Agilent Technologies (NYSE:A) Posts Earnings Results, Beats Expectations By $0.04 EPS

Agilent Technologies (NYSE:A) issued its earnings results on Wednesday. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04, Zacks reports. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.58%. The firm had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies updated its Q2 2025 guidance to 1.250-1.280 EPS and its FY 2025 guidance to 5.540-5.610 EPS.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $127.07 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The firm has a market cap of $36.25 billion, a price-to-earnings ratio of 29.21, a price-to-earnings-growth ratio of 3.64 and a beta of 1.07. The business has a 50-day simple moving average of $140.78 and a two-hundred day simple moving average of $139.20. Agilent Technologies has a fifty-two week low of $124.16 and a fifty-two week high of $155.35.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.78%. Agilent Technologies’s payout ratio is 22.76%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on A. Sanford C. Bernstein cut their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. JPMorgan Chase & Co. decreased their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, November 26th. Robert W. Baird reduced their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research report on Thursday. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Finally, StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $146.15.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.